Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000

Vetsika Eleni-Kyriaki, Papadimitraki Elisavet, Aggouraki Despoina, Konsolakis Georgios, Mela Marina-Eleni, Kotsakis Athanasios, Christou Soultana, Patramani Stefania, Alefantinou Marina, Kaskara Ageliki, Christophyllakis Charalampos, Kosmatopoulos Kostas, Georgoulias Vassilis, Mavroudis Dimitris

Abstract excerpt

The aim of this study was to investigate the best administration of telomerase reverse transcriptase (TERT572), an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase, and its optimized variant TERT(572Y) to elicit specific T cell immune responses in cancer patients. Forty-eig...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Clinical Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunospot Assay

Share to Epitopes, T-Lymphocyte

Share to HLA-A2 Antigen

Share to Interferon-gamma

Share to Telomerase

Share to Vaccination

Source

Identifiers

PMID: 21989412
DOI: 10.1097/CJI.0b013e31823284a6

Genes

TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21989412-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.PMID 21989412Read ↗

Telomerase and CD4 T Cell Immunity in CancerSemantic proximity Read ↗

Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.Semantic proximity Read ↗

Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesSemantic proximity Read ↗

Anti-Cancer Immunotherapies Targeting TelomeraseSemantic proximity Read ↗

Clinical research progress of telomerase targeted cancer immunotherapy: a literature reviewSemantic proximity Read ↗

Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV Related Liver CancerSemantic proximity Read ↗

Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.Semantic proximity Read ↗

Cytotoxic T cell immunity against telomerase reverse transcriptase in humansSemantic proximity Read ↗

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer.Semantic proximity Read ↗

Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell ResponsesSemantic proximity Read ↗

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.